OSE Immunotherapeutics SA

05/22/2024 | Press release | Distributed by Public on 05/22/2024 01:11

OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first in class treatments for cancer and cardio renal metabolic diseases